Abstract
Sudden cardiac arrest is a leading cause of death worldwide with survival rates still remaining suboptimal. Unfortunately, most cardiac arrest patients, who achieve return of spontaneous circulation (ROSC), develop a multi-faceted post-cardiac arrest syndrome, including post-cardiac arrest brain injury, myocardial dysfunction, and systemic ischemia/reperfusion response.
Erythropoietin (EPO), the principal hematopoietic hormone regulating erythropoiesis, exhibits diverse cellular effects in nonhematopoietic tissues. Due to its anti-apoptotic, anti-inflammatory, and anti-oxidant properties, as well as its angiogenic action, EPO plays a role in neuroprotection and cardioprotection. In this regard, EPO represents a promising agent in the cardiac arrest setting, based on a therapeutic strategy that focuses on the post-resuscitation phase.
This review aims to provide a comprehensive account of EPOs role in the treatment of each individual component of post-cardiac arrest syndrome.
Keywords: Erythropoietin, Cardiac arrest, Post-cardiac arrest syndrome, Neuroprotection, Cardioprotection, Anti-oxidant, hematopoietic, heterotrimer, dysfunction, reperfusion, homeostasis, cardiopulmonary, leukocytes, apoptotic, P-selectin, astrocytes, hypoxic, necrosis
Current Pharmaceutical Design
Title: The Potential Role of Erythropoietin as a Pleiotropic Agent in Post-cardiac Arrest Syndrome
Volume: 17 Issue: 15
Author(s): Theodoros Xanthos, Panagiotis V.S. Vasileiou, Sotirios Kakavas, Aggeliki Syggelou and Nicoletta Iacovidou
Affiliation:
Keywords: Erythropoietin, Cardiac arrest, Post-cardiac arrest syndrome, Neuroprotection, Cardioprotection, Anti-oxidant, hematopoietic, heterotrimer, dysfunction, reperfusion, homeostasis, cardiopulmonary, leukocytes, apoptotic, P-selectin, astrocytes, hypoxic, necrosis
Abstract: Sudden cardiac arrest is a leading cause of death worldwide with survival rates still remaining suboptimal. Unfortunately, most cardiac arrest patients, who achieve return of spontaneous circulation (ROSC), develop a multi-faceted post-cardiac arrest syndrome, including post-cardiac arrest brain injury, myocardial dysfunction, and systemic ischemia/reperfusion response.
Erythropoietin (EPO), the principal hematopoietic hormone regulating erythropoiesis, exhibits diverse cellular effects in nonhematopoietic tissues. Due to its anti-apoptotic, anti-inflammatory, and anti-oxidant properties, as well as its angiogenic action, EPO plays a role in neuroprotection and cardioprotection. In this regard, EPO represents a promising agent in the cardiac arrest setting, based on a therapeutic strategy that focuses on the post-resuscitation phase.
This review aims to provide a comprehensive account of EPOs role in the treatment of each individual component of post-cardiac arrest syndrome.
Export Options
About this article
Cite this article as:
Xanthos Theodoros, V.S. Vasileiou Panagiotis, Kakavas Sotirios, Syggelou Aggeliki and Iacovidou Nicoletta, The Potential Role of Erythropoietin as a Pleiotropic Agent in Post-cardiac Arrest Syndrome, Current Pharmaceutical Design 2011; 17 (15) . https://dx.doi.org/10.2174/138161211796197115
DOI https://dx.doi.org/10.2174/138161211796197115 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antithrombotic Therapy in Cardiac Embolism
Current Cardiology Reviews Recent Development of Hydrogen Sulfide Therapeutics in the Treatment of Cardiovascular Diseases
Current Topics in Medicinal Chemistry Prognostic Relevance of Metabolic Approach in Patients with Heart Failure
Current Pharmaceutical Design Surgical Ventricular Restoration to Reverse Left Ventricular Remodeling
Current Cardiology Reviews The Pivotal Role of Nitric Oxide: Effects on the Nervous and Immune Systems
Current Pharmaceutical Design Delivery of Peptides Via the Oral Route: Diabetes Treatment by Peptide-Loaded Nanoparticles
Current Pharmaceutical Design A Series of Novel Neuroprotective Blood Brain Barrier Penetrating Flavonoid Drugs to Treat Acute Ischemic Stroke
Current Pharmaceutical Design Adrenomedullin Function in Vascular Endothelial Cells: Insights from Genetic Mouse Models
Current Hypertension Reviews An Overview of Acute Flaccid Myelitis
CNS & Neurological Disorders - Drug Targets Role of PPAR in Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery A Very Rare Cerebral Complication of Chemotherapy in a Young Girl: A Difficult Diagnosis
Current Drug Safety Combining Growth Factor and Stem Cell Therapy for Stroke Rehabilitation, A Review
Current Drug Targets Current Outcomes and Considerations in Hypoplastic Left Heart Syndrome
Current Pediatric Reviews Design of Iodine-Lithium-α-Dextrin Liquid Crystal with Potent Antimicrobial and Anti-Inflammatory Properties
Current Pharmaceutical Design Polypharmacology of <i>Aconitum</i> and <i>Delphinium</i> sp. Diterpene Alka loids: Antiarrhythmic, Analgesic and Anti-Inflammatory Effects
Mini-Reviews in Organic Chemistry Modulating Mitochondria-Mediated Apoptotic Cell Death through Targeting of Bcl-2 Family Proteins
Recent Patents on DNA & Gene Sequences Ipsilateral Hippocampal Proteomics Reveals Mitochondrial Antioxidative Stress Impairment in Cortical-Lesioned Chronic Mild Stressed Rats
Current Molecular Medicine Heme Oxygenase-1/Carbon Monoxide: Novel Therapeutic Strategies in Critical Care Medicine
Current Drug Targets The Integral Nuclear Membrane Protein Nurim Plays a Role in the Suppression of Apoptosis
Current Molecular Medicine Endotoxin, TLR4 Signaling and Vascular Inflammation: Potential Therapeutic Targets in Cardiovascular Disease
Current Pharmaceutical Design